SG10201700872TA - NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION - Google Patents
NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATIONInfo
- Publication number
- SG10201700872TA SG10201700872TA SG10201700872TA SG10201700872TA SG10201700872TA SG 10201700872T A SG10201700872T A SG 10201700872TA SG 10201700872T A SG10201700872T A SG 10201700872TA SG 10201700872T A SG10201700872T A SG 10201700872TA SG 10201700872T A SG10201700872T A SG 10201700872TA
- Authority
- SG
- Singapore
- Prior art keywords
- procnp
- biomarker
- vascular disorders
- pregnancy complication
- pregnancy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261682729P | 2012-08-13 | 2012-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201700872TA true SG10201700872TA (en) | 2017-04-27 |
Family
ID=50101335
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201700872TA SG10201700872TA (en) | 2012-08-13 | 2013-08-13 | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
SG11201501145SA SG11201501145SA (en) | 2012-08-13 | 2013-08-13 | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201501145SA SG11201501145SA (en) | 2012-08-13 | 2013-08-13 | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
Country Status (9)
Country | Link |
---|---|
US (1) | US10012656B2 (en) |
EP (1) | EP2883060B1 (en) |
JP (1) | JP6423788B2 (en) |
CN (1) | CN104937420B (en) |
AU (1) | AU2013303302B2 (en) |
CA (1) | CA2882116A1 (en) |
IN (1) | IN2015KN00571A (en) |
SG (2) | SG10201700872TA (en) |
WO (1) | WO2014027899A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
SG10201700872TA (en) * | 2012-08-13 | 2017-04-27 | Otago Innovation Ltd | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
WO2016064815A1 (en) * | 2014-10-20 | 2016-04-28 | Massachusetts Institute Of Technology | Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers |
WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
TWI776812B (en) * | 2016-06-02 | 2022-09-11 | 荷蘭商菲林公司 | Angiotensin-1-receptor antagonists |
JP7270912B2 (en) * | 2017-05-22 | 2023-05-11 | 東ソー株式会社 | Information provision method for prognosis prediction by adrenomedullin concentration fluctuation and its reagent |
WO2019199871A1 (en) * | 2018-04-10 | 2019-10-17 | Quanterix Corporation | Quantification of neurofilament light chain in physiological samples |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT407580B (en) * | 1999-08-20 | 2001-04-25 | Biomedica Gmbh | INDICATOR PEPTIDE FOR DIAGNOSIS AND / OR PREDICTION OF CARDIOVASCULAR AND / OR ENDOTHELIAL DISEASES, ANTIBODY COMPOSITION AND IMMUNOASSAY |
WO2004099139A1 (en) | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
DK1644740T3 (en) * | 2003-06-17 | 2011-02-21 | Otago Innovation Ltd | Assessment of skeletal growth using measurements of NT-CNP peptides |
DE10338733A1 (en) | 2003-08-22 | 2005-03-24 | Berdel, Wolfgang E., Prof. Dr.med. | Fusion polypeptides and their use for antivascular tumor therapy |
WO2008042855A2 (en) | 2006-09-29 | 2008-04-10 | The Trustees Of The University Of Pennsylvania | Use of ultrasound as an antivascular agent |
JP5684904B2 (en) * | 2010-06-18 | 2015-03-18 | セザンヌ ソシエテ パ アクシオンス シンプリフィエ | Markers for prognosis and risk assessment of preeclampsia and preeclampsia |
US20150293119A1 (en) | 2011-12-23 | 2015-10-15 | Mayo Foundation For Medical Education And Research | Assessing renal structural alterations and outcomes |
SG10201700872TA (en) * | 2012-08-13 | 2017-04-27 | Otago Innovation Ltd | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
-
2013
- 2013-08-13 SG SG10201700872TA patent/SG10201700872TA/en unknown
- 2013-08-13 CA CA2882116A patent/CA2882116A1/en not_active Abandoned
- 2013-08-13 WO PCT/NZ2013/000142 patent/WO2014027899A1/en active Application Filing
- 2013-08-13 IN IN571KON2015 patent/IN2015KN00571A/en unknown
- 2013-08-13 SG SG11201501145SA patent/SG11201501145SA/en unknown
- 2013-08-13 US US14/421,423 patent/US10012656B2/en not_active Expired - Fee Related
- 2013-08-13 AU AU2013303302A patent/AU2013303302B2/en not_active Ceased
- 2013-08-13 JP JP2015527420A patent/JP6423788B2/en not_active Expired - Fee Related
- 2013-08-13 CN CN201380053106.1A patent/CN104937420B/en not_active Expired - Fee Related
- 2013-08-13 EP EP13829360.0A patent/EP2883060B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
US10012656B2 (en) | 2018-07-03 |
CA2882116A1 (en) | 2014-02-20 |
CN104937420B (en) | 2018-07-03 |
CN104937420A (en) | 2015-09-23 |
WO2014027899A1 (en) | 2014-02-20 |
AU2013303302B2 (en) | 2017-10-12 |
EP2883060A1 (en) | 2015-06-17 |
EP2883060A4 (en) | 2016-06-29 |
SG11201501145SA (en) | 2015-04-29 |
IN2015KN00571A (en) | 2015-07-17 |
US20150241451A1 (en) | 2015-08-27 |
EP2883060B1 (en) | 2018-03-21 |
JP6423788B2 (en) | 2018-11-14 |
AU2013303302A1 (en) | 2015-03-12 |
JP2015526725A (en) | 2015-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1201452A1 (en) | Methods of reducing risk of cardiovascular disease | |
HK1202545A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
EP2922861A4 (en) | Biomarker compositions and methods | |
EP2895067A4 (en) | Evaluation of movement disorders | |
EP2823306A4 (en) | Biomarker compositions and methods | |
GB201423360D0 (en) | Adaptive clustering of locations | |
SG11201501145SA (en) | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION | |
ZA201502336B (en) | Enzalutamide polymorphic forms and its preparation | |
GB2499463A8 (en) | Reduced sugar syrups and methods of making reducedsugar syrups | |
EP2852397A4 (en) | Huwentoxin-iv variants and methods of use | |
HK1203464A1 (en) | Automatic and vital determination of train length configuration | |
ZA201405206B (en) | Multifunctional structure and method for its manufacture | |
EP2881113A4 (en) | New application of pogostone | |
GB2502110B (en) | Chips and manufacture thereof | |
GB201214362D0 (en) | Conical transition piece | |
IL237862A0 (en) | Methods of reducing scalant formation | |
PL2903448T3 (en) | Hard confectionary and method of manufacture thereof | |
PT2861242T (en) | Gluten-related disorders | |
GB2503216B (en) | Continuity of content | |
EP2852971A4 (en) | Semiconductor constructions and methods of forming semiconductor constructions | |
IL239426A0 (en) | Biomarker methods and compositions | |
ZA201500353B (en) | Method of ameliorating clotting pathologies and related materials and methods | |
GB201416065D0 (en) | Catalysts and methods of making and using catalysts | |
GB201609028D0 (en) | Adaptive clustering of locations | |
PL2931929T3 (en) | Alloy for the production of jewels |